the the applications Thank audits Mark want or Medical by European results was to revenue for you, joining MDR, new delays due process. to of of for a of Device the our This Chuck. I shipments and note CE And in were CGuard bodies recertification well-documented temporary November a on as our the the by thanks Regulation, the XXXX. start XX, impacted expiration with under call. cessation regulatory significant to due processing everyone quarter regulatory this to morning fourth
replaced for to and at XXXX. and entire EU has Device MDR requirement changes, updated markets industry MDR devices device taken deadline more had the governed which historically EU of the years Medical or By transition with marketing The the putting until delays the the the risk. May serving revisions, approval than Directive, three MDD, background, medical way of in medical certification multiple
complexity, situation. a changing constantly deadlines market precarious This very the requirements has forced into the with combined and
Our position guidelines new of prudent of follow compliance beginning as all introductions was certification. to mandated the from the requiring measure MDR for new product long-term this a
our our have notified the body of the complete the throughout the worked prior expiration to we XXXX, on to process on lost XX, MDD Due to with our date. scheduling our tirelessly markets sell ability this November final to We chronic temporarily delays in uncertainty. audit of certification that EU
efforts, In revenue much best certificate anticipation, expiration. available partners fourth proactively our continuing possible to to to complete distributor reestablish of shortages following process reflects sales. as with provide Despite worked a shortfall to avoid while as MDR our inventory the quarter shipments we our the
approximately fourth revenue to totaled interruption, recorded $X.X a our revenue. Mark. been CE million after CGuard the shipped of approximately we operate Had the quarter $XXX,XXX carryforward would we in Therefore, not of able this backlog, without loss in $X,XXX,XXX have with
were under we in jurisdictions our this through and countries as believe our measure a However, to imminent. previous to to certificate all work we earlier we temporary I'm be report steps final able shift EU the our that pleased and which Mark MDR other reinstate CE MDD month, as to certification,
CGuard of although taking life-saving March quarter, to XX. the effective priority, the patient we care stent ensure interruption. every And availability channels in the and shipments late without for platform as a step resumed refill We are
market a the first this foundation serve MDR the be long well to drive soon. will us EU. receive term, growth has we will Managing companies challenging, this one turbulent to the And but in the transition very as been we certification for of anticipate continuing of
We currently served market with some over exceeding XX%. share in our than greater of enjoy markets territories XX% half
launch platform stent endovascular the this of on growth with efforts enable of two standard-of-care together and advanced CGuard new next-generation system. transfemoral will ground, to delivery conversion continued new share with surgeries systems, the accelerate stent Our near-term the transcarotid including and a
as And turning our enrollment anticipate this IDE to in the trial U.S. regulatory the a in potential submission to activities, next at our CGuard enrollment we now C-Guardians the quarter. enrollment closer steps active sites. enable remarkable with approval U.S. Achieving will We trial pace of and milestone of U.S. launch completing continues XX get process next market.
added the we leadership Shane go-to-market have a the launch, will U.S. team seasoned Marketing Global continue in in market Strategy. to of of vascular the preparation executive lead GM Americas who as preparation commercial we the space, and As invest to Gleason our
to terms of remains two drive CGuard realize developed potential pipeline, the specialist fully EPS we've believe important vascular implant CGuard of product delivery focus to and across foundation delivery our our broadest selected order In In patient stent on remains of systems new platform variable the the we of the however, the importance single beyond the most community. the business, outcomes to utilization option.
versions method kit development, those We choosing of TCAR the transfemoral our best TCAR accessory we combination, approval neuroprotection. our with and continue plans launch delivery for solution system, will device. available the will both of CGuard with this transcarotid development and our short which enable new standard In to regulatory in compatible to utilize stent be SwitchGuard, believe shaft Prime, advance for
best the rapidly can of the forward potential we tirelessly goal establish to and look catalyst-rich toward with a our offer this outcomes EPS, We how CGuard continue evolving are unlock to to broadest strokes standard of CGuard tremendous disease continue XXXX paradigm of carotid the believe prevented. With managed is We to segment. care. as as the the patient changing work set we market we of of tools
I'll of Craig? our for review quarter turn over first call to With that, Craig the the financials.